The mild mdx mice are now complemented by numerous background and mutation variants that can better mimic affected humans.
It was recognized only recently in the studies of Yokota (N = 229) [ 13] and Imamura (N = 1261) [ 14] that the prognostic significance of KRAS mutation can be better examined in BRAF wild-type CRCs, because almost all BRAF mutant patients are KRAS wild-type.
If we can anticipate how the cancer in patient 1 with driver oncogenic mutation A will evolve in response to a drug targeting oncogene A, which could be different from the cancer in patient 2 with oncogenic mutation X, then we can better treat each patient.
We have shown that by invoking heterogeneities in mutation and recombination rates, one can better explain the observed variation in SNP density across two randomly sampled 100 kb segments of human chromosomes.
In addition, haplotypes can better capture mutations in more than one loci.
Compared with diploids, polyploid species can better withstand higher mutation densities because of compensation by other genome copies [ 4, 5], as additional gene copies may mask the phenotypic effect of a mutation.
In the process called adaptation, selection for beneficial mutations can cause a species to evolve into forms better able to survive in their environment.
Possibly, better estimates of risk for individuals in populations with founder mutations can be calculated.
Mutations can slow the process down in many ways.
Hundreds of mutations can cause varying degrees of muscular dystrophy.
